ASCO 2017 | MRD: an important topic in myeloma therapy
Sagar Lonial
• 2 Jun 2017
Sagar Lonial, MD, FCAP, from the Winship Cancer Institute, Atlanta, GA, talks about why minimal residual disease (MRD) is an important topic in myeloma therapy. He explains that conventional complete remission (CR) is not enough to help us assess the depth of response. We need to understand what MRD status tells us. Patients who achieve MRD negativity clearly have better survival, both progression free and overall survival than patients who don’t, but we do not have data that tells us exactly what to do in certain situations. Questions must be asked about standardisation and about how to utilize that data and what time points are important.
